Angiogenic Factors Regulate Tumorigenicity and Metastasis of Human Transitional Cell Carcinoma in the Urinary Bladder

血管生成因子调节人膀胱移行细胞癌的致瘤性和转移

基本信息

  • 批准号:
    12671540
  • 负责人:
  • 金额:
    $ 2.3万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2000
  • 资助国家:
    日本
  • 起止时间:
    2000 至 2001
  • 项目状态:
    已结题

项目摘要

Purpose : This study was designed to determine the relative activity of basic fibroblast growth factor (bFGF), vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), and interleukin-8 (IL-8) in the process of regulating tumorigenicity and metastasis of transitional cell carcinoma (TCC) of the urinary bladder.Experimental Design : We selected the specific expression clones as indicated to the expression level of bFGF, VEGF or IL-8 m highly tumorigenic and highly metastatic human TCC cell line 253JB-V. We evaluated transitionally tumorigemcily and production of spontanous lymph node metastases after orthotopic implantation of the specific expression clones. To assess the transitional changes of angiogenesis and the expression of angiogenic factors, intratumor neovascularization and mRNA expression of angiogenic factors were determined in the tumors.Results : In vitro, the highest and lowest specific expression clones demonstrated stable expression of specific total R … More NA and protein. Following implantation into the bladders of athymic nude mice, the highest bFGF- and the highest IL-8-expressing clone cells acquired increased tumorigenicity in only early stage. Moreover, the tumorigenicity of the lowest bFGF- and the lowest IL-8-expressing clone were consistently inhibited through all stages compared to parental 253JB-V cell lines. The highest bFGF- and the highest IL-8-expressing clone cells relatively acquired matastasis in earlier stage. Moreover, the metastasis of the lowest IL-8-expressing clone was relatively inhibited compared to parental 253JB-V cell lines. However, the tumorigenicity and metastasis of the specific expression clones of VEGF were not significantly different from that of parental 253JB-V cell lines.In the tumors, each highest expressing clone significantly increased the specific mRNA expression and neovascularity, and each lowest expressing clone significantly decreased specific mRNA expression and neovascularity in only early stage compared to parental 253JB-V cell lines. However, the intratumor neovascularity and the expression level or bFGF, VEGF and IL-8 in the tumor of the specific expression clones were gradually regulated to the same expression level as parental 253JB-V cell lines within 4 weeks.Conclusions : These findings indicate that the expression of bFGF regulates angiogenesis, tumorigenicity especially in early stage of tumor progression of human TCC growing in the urinary bladder of athymic nude mice. Thereore, this study provided tha evidence that the therapy targeting angiogenesis pathways such as bFGF represents a novel, effective, and promising therapy with significant anti-tumoral effect, in the early stage of tumor progression of TCC in the urinary bladder. Less
目的:探讨碱性成纤维细胞生长因子(BFGF)、血管内皮生长因子/血管通透性因子(VEGF/VPF)和白介素8(IL-8)在调节膀胱移行细胞癌(TCC)发生和转移过程中的相对活性。我们对特定表达克隆原位移植后的肿瘤发生和自发性淋巴结转移的产生进行了过渡性评估。结果:在体外,特异性表达最高和最低的克隆均能稳定表达特异性总R-…更多的NA和蛋白质。移植到裸鼠膀胱中后,bFGF和IL-8表达最高的克隆细胞仅在早期获得了更高的致瘤性。此外,与亲本253JB-V细胞系相比,表达最低bFGF和最低IL-8的克隆的致瘤性在所有阶段都受到持续抑制。BFGF-和IL-8表达最高的克隆细胞在早期相对获得转移。此外,与亲本253JB-V细胞系相比,IL-8表达最低的克隆的转移受到相对抑制。与亲本253JB-V细胞相比,各高表达克隆的成瘤性和转移性差异无统计学意义,各高表达克隆均显著增强肿瘤细胞的特异性mRNA表达和新生血管,低表达克隆仅在早期显著降低特异性mRNA表达和新生血管。而在4周内,特异性表达克隆的肿瘤内新生血管和bFGF、VEGF、IL-8的表达水平逐渐被调节到与亲代253JB-V细胞相同的表达水平。结论:bFGF的表达调控裸鼠膀胱癌的血管生成和致瘤性,尤其是在肿瘤进展的早期阶段。因此,本研究为血管生成通路的靶向治疗在膀胱移行细胞癌的早期进展中提供了一种新的、有效的、有希望的治疗方法,具有显著的抗肿瘤作用。较少

项目成果

期刊论文数量(18)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Inoue K, Chikazawa M, Fukata S, Yoshikawa C, Shuin T.: "Frequent Administration of Angiogenesis Inhibitor TNP-470 (AGM-1470) at an Optimal Bikological Dose Inhibits Tumor Growth and Metastasis of Metastatic Human Transitional Cell Carcinoma in the Urinary
Inoue K、Chikazawa M、Fukata S、Yoshikawa C、Shuin T.:“以最佳生物剂量频繁施用血管生成抑制剂 TNP-470 (AGM-1470) 可抑制泌尿系转移性人类移行细胞癌的肿瘤生长和转移
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Inoue K, Chikazawa M, Fukata S, Yoshikawa C, Shuin T: "Docetaxel (Taxotare) Enhances the Therapeutic Effect of the Angiogenesis Inhibitor TNP-470 (AGM-1470) in Metastatic Human Transitional Cell Carcinoma"Clin Cancer Res.. 9. 886-899 (2003)
Inoue K、Chikazawa M、Fukata S、Yoshikawa C、Shuin T:“多西他赛(泰索太)增强血管生成抑制剂 TNP-470 (AGM-1470) 在转移性人类移行细胞癌中的治疗效果”临床癌症研究 9。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Inoue K: "Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antbody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma"Clin Cancer Res. 6(12). 4874-4884 (2000)
Inoue K:“紫杉醇增强抗表皮生长因子受体单克隆抗体 ImClone C225 对转移性人膀胱移行细胞癌小鼠的作用”Clin Cancer Res。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Inoue K, Shuin T, et al.: "Docetaxel (Taxotare) Enhances the Therapeutic Effect of the Angiogenesis Inhibitor TNP-470 (AGM-1470) in Metastatic Human Transitional Cell Carcinoma"Clin Cancer Res.. 9. 886-899 (2003)
Inoue K、Shuin T 等:“多西紫杉醇 (Taxotare) 增强血管生成抑制剂 TNP-470 (AGM-1470) 在转移性人类移行细胞癌中的治疗效果”Clin Cancer Res.. 9. 886-899 (2003)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP: "Pacilitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bl
Inoue K、Slaton JW、Perrotte P、Davis DW、Bruns CJ、Hicklin DJ、McConkey DJ、Sweeney P、Radinsky R、Dinney CP:“紫杉醇增强抗表皮生长因子受体单克隆抗体 ImClone C225 在小鼠体内的作用
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

INOUE Keiji其他文献

INOUE Keiji的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('INOUE Keiji', 18)}}的其他基金

Elucidation of the function and the anti-tumor effects of heme oxygenase-1(HO-1) in bladder cancer.
阐明血红素加氧酶-1(HO-1)在膀胱癌中的功能和抗肿瘤作用。
  • 批准号:
    26462414
  • 财政年份:
    2014
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Comprehensive gene analysis of false positive urothelium in photodynamic diagnosis to explore the novel carcinogenesis-related gene
光动力诊断中假阳性尿路上皮的综合基因分析,探索新型致癌相关基因
  • 批准号:
    23592335
  • 财政年份:
    2011
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel Therapeutic Strategy Based on Systematic Regulation of Metastasis-related Genes Expression in Human Transitional Cell Carcinoma of the Urinary Bladder
基于系统调节人膀胱移行细胞癌转移相关基因表达的新治疗策略
  • 批准号:
    15591692
  • 财政年份:
    2003
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research of gene therapy for liver cirrhosis and fibrosis, using solble TGF-beta receptor.
利用可溶性TGF-β受体进行肝硬化和纤维化基因治疗的研究。
  • 批准号:
    08457305
  • 财政年份:
    1996
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)

相似海外基金

Regulatory Role of Mitochondrial DNA in Bladder Cancer Progression
线粒体 DNA 在膀胱癌进展中的调节作用
  • 批准号:
    10575847
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
Effectors of protein kinase C-mediated tumor progression
蛋白激酶 C 介导的肿瘤进展的效应器
  • 批准号:
    10543367
  • 财政年份:
    2022
  • 资助金额:
    $ 2.3万
  • 项目类别:
Targeting colorectal cancer stem cells with ALDH1B1 antagonists
使用 ALDH1B1 拮抗剂靶向结直肠癌干细胞
  • 批准号:
    10640894
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
Targeting colorectal cancer stem cells with ALDH1B1 antagonists
使用 ALDH1B1 拮抗剂靶向结直肠癌干细胞
  • 批准号:
    10407067
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
Targeting colorectal cancer stem cells with ALDH1B1 antagonists
使用 ALDH1B1 拮抗剂靶向结直肠癌干细胞
  • 批准号:
    10299142
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
Kinase signaling during mammary tumor initiation
乳腺肿瘤发生过程中的激酶信号传导
  • 批准号:
    9445042
  • 财政年份:
    2017
  • 资助金额:
    $ 2.3万
  • 项目类别:
Role of hedgehog signaling in tumor-associated macrophage polarization
Hedgehog信号在肿瘤相关巨噬细胞极化中的作用
  • 批准号:
    9394849
  • 财政年份:
    2017
  • 资助金额:
    $ 2.3万
  • 项目类别:
Elucidating roles for the heparan sulfate and chondroitin sulfate glycosaminoglycan chains on Betaglycan in Wnt Signaling
阐明 Betaglycan 上的硫酸乙酰肝素和硫酸软骨素糖胺聚糖链在 Wnt 信号转导中的作用
  • 批准号:
    9261044
  • 财政年份:
    2016
  • 资助金额:
    $ 2.3万
  • 项目类别:
Ect2 Function in Lung Adenocarcinoma Initiation and Maintenance
Ect2 在肺腺癌发生和维持中的功能
  • 批准号:
    9095722
  • 财政年份:
    2016
  • 资助金额:
    $ 2.3万
  • 项目类别:
Effectors of protein kinase C-mediated tumor progression
蛋白激酶 C 介导的肿瘤进展的效应器
  • 批准号:
    9198206
  • 财政年份:
    2016
  • 资助金额:
    $ 2.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了